Perceptive Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Perceptive Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.6M	Buy	+1,755,799	New	+$24.7M	0.74%	33
2022 Q3	–	Sell	-556,047	Closed	-$9.95M	–	118
2022 Q2	$9.95M	Hold	556,047	–	–	0.31%	60
2022 Q1	$5.52M	Hold	556,047	–	–	0.11%	101
2021 Q4	$9.37M	Hold	556,047	–	–	0.14%	99
2021 Q3	$13.2M	Sell	556,047 -200,000	-26%	-$4.79M	0.19%	88
2021 Q2	$17.2M	Buy	+756,047	New	+$15.8M	0.22%	86

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Perceptive Advisors's DAWN Position: Q1 2026 in Review

Perceptive Advisors opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 1,755,799 shares worth $37.6M. The stake represents 0.74% of the portfolio and ranks #33 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in DAWN as recently as Q2 2022.

Perceptive Advisors first reported a position in DAWN in Q2 2021 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Perceptive Advisors held 1,755,799 shares of Day One Biopharmaceuticals worth $37.6M as of Q1 2026.
Day One Biopharmaceuticals was a new Perceptive Advisors position in Q1 2026.
Day One Biopharmaceuticals made up 0.74% of Perceptive Advisors's portfolio in Q1 2026, its #33 holding.
Perceptive Advisors first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 6 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.